Lung Adenocarcinoma : EGFR Amplification and Mutation Analysis

Test Information

For Lung Adenocarcinoma, GGC offers amplification and mutation analysis of EGFR exons 18-21

Turnaround Time

10 days

CPT Code(s)





Clinical Information

EGFR Amplification and Mutation Analysis: Mutations in exons 18-21 of epidermal growth factor receptor (EGFR), for example, are reported to provide valuable information on sensitivity to EGFR inhibitors. These mutations occur in around 10% of all lung adenocarcinomas with estimates of up to 40% in some Asian cohorts (BMC Pulmonary Medicine (2016) 16(1):88). The predictive information afforded by EGFR mutational testing in exons 18-21 has led NCCN to recommend patients diagnosed with non-squamous NSCLC or NSCLC not otherwise specified have EGFR mutation testing.


Gene sequencing and targeted mutation testing and copy number analysis can serve as a useful diagnostic and potentially prognostic tool for the analysis of affected tissues or tumors. The detection of copy number variants or specific gene mutations may enhance treatment decisions.

Specimen Requirements

Analysis can be performed on fresh or frozen tissue samples as well as formalin-fixed, paraffin-embedded tissue samples.

Transport Instructions

The specimen should be kept at the appropriate temperature and delivered via overnight shipping.

Have Questions Need Support?

Call our laboratory at 1-800-473-9411 or contact one of our Laboratory Genetic Counselors for assistance.
Robin Fletcher, MS, CGC
Kellie Walden, MS, CGC

Oncology Testing, Targeted Variants
Meet Makayla Gunn

Meet Makayla Gunn

Makayla was diagnosed with Rett Syndrome in April of 2015 at the age of two.   At about 18 months, we noticed she had started some repetitive hand motions, and her pediatrician was a little concerned that she did not have many words.  She had learned some sign language, and was saying ‘mama’ and ‘dada’, but that was it.  Then she suddenly stopped all of that.  At her 2 year old check-up, the pediatrician referred us to BabyNet, ...

In The News